All In Biotech

Drug Trial Radar · NCT00658775

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Last checked: Nov 20, 2026Latest source record: Dec 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,069 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,069

Actual

Start

Feb 2008

Primary completion

Sep 2009

Study completion Jan 2010

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Apr 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • Rabeprazole sodiumDrug

    Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

  • EsomeprazoleDrug

    Esomeprazole 40 mg capsule, once daily for 4-8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksTime frame: Baseline and Week 8
  2. Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 WeeksTime frame: Baseline and Week 4

Locations

83 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Moline, Illinois

  • Site not named

    La Plata, Argentina, Argentina

  • Site not named

    Buenos Aires, BUE, Argentina

  • Site not named

    Buenos Aires, BUE, Argentina

  • Site not named

    Ciudad Autonoma de Bs. As., CBA, Argentina

  • Site not named

    Ciudad Autonoma de Bs. As., CBA, Argentina

  • Site not named

    Ciudad Autonoma de Bs. As., CBA, Argentina

  • Site not named

    Rosario, SFE, Argentina

  • Site not named

    San Miguel de Tucumán, TUC, Argentina

  • Site not named

    Penrith, New South Wales, Australia

  • Site not named

    Caboolture, Queensland, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Woodville, South Australia, Australia

  • Site not named

    Launceston, Tasmania, Australia

  • Site not named

    Ballarat, Victoria, Australia

  • Site not named

    Fitzroy, Victoria, Australia

  • Site not named

    Haskovo, Bulgaria, Bulgaria

  • Site not named

    Plovdiv, Bulgaria, Bulgaria

  • Site not named

    Rousse, Bulgaria, Bulgaria

  • Site not named

    Sofia, Bulgaria, Bulgaria

  • Site not named

    Sofia, Bulgaria, Bulgaria

  • Site not named

    Barrie, Ontario, Canada

  • Site not named

    Chatham, Ontario, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Richmond Hill, Ontario, Canada

  • Site not named

    Sarnia, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Sherbrooke, Quebec, Canada

  • Site not named

    Saskatoon, Saskatchewan, Canada

  • Site not named

    Providencia, Chile, Chile

  • Site not named

    Santiago, Chile, Chile

  • Site not named

    Temuco, Chile, Chile

  • Site not named

    Osijek, Croatia, Croatia

  • Site not named

    Split, Croatia, Croatia

  • Site not named

    Zagreb, Croatia, Croatia

  • Site not named

    Tallinn, Estonia, Estonia

  • Site not named

    Tallinn, Estonia, Estonia

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.